Hintergrund: Bei fortgeschrittenen malignen hämatologi-schen Erkrankungen wird häufig eine allogene Stammzelltransplantation (alloHSZT) durchgeführt, die jedoch auf Grund der hohen behandlungsassoziierten Mortalität und einem hohen Rezidivrisiko nur bei einem Teil der Patienten lebensverlängernd ist. Patienten und Methoden: Um Variablen zu analysieren, die mit dem Erfolg einer alloHSZT bei fortgeschrittenen malignen hämatologischen Erkrankungen asso ziiert sind, wurde eine retrospektive, multizentrische Erhebung an 401 Patienten durchgeführt. Dabei wurden unabhängige prognostische Faktoren bezüglich des Gesamtüber lebens (OS) und des erkrankungsfreien Überlebens (DFS) in der multi variaten Analyse unter Verwendung des proportionalen HazardModells (Cox-Modell) untersucht. Ergebnisse: Das OS und DFS betrug nach 5 Jahren 27,3 bzw. 21,1%. In der multivariaten Analyse konnte gezeigt werden, dass die zugrunde liegende maligne Erkrankung einen signifikanten Einfluss auf das OS und das DFS hat (p < 0,001 und 0,011), während das Auftreten einer schweren akuten Graft-versus-Host-Reaktion (GvHD) einen negativen Einfluss auf das OS hatte (p < 0,001). Das Auftreten einer chronischen GvHD zeigte einen Trend für ein besseres OS (p = 0,085) und DFS (p = 0,199). Die Intensität der Konditionierungstherapie hatte hingegen keinen Einfluss auf das OS und DFS. Schlussfolgerung: Die Verbesserung des Ergebnisses nach alloHSZT bei fortgeschrittenen hämatologischen Erkrankungen infolge des Auftretens einer chronischen GvHD aber nicht infolge der Konditionierungstherapie unterstreicht die Bedeutung des mit der chronischen GvHD assoziierten Graft-versus-Leukämie-Effekts.
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is often performed in cases of advanced hematological diseases, but because of the associated mortality and a high risk of relapse it is life prolonging only in some patients. Patients and Methods: A retrospective multi-center analysis of 401 patients was conducted to analyze the variables associated with outcome after alloHSCT in advanced hematological diseases. The Cox proportional hazards model was used to assess the independence of overall survival (OS) and disease-free survival (DFS) from prognostic factors in a multivariate model. Results: The 5-year OS and DFS were 27.3 and 21.1% respectively. Multivariate analysis showed that the underlying malignancy had a significant influence on OS and DFS (p < 0.001 and p < 0.011, respectively), whereas development of severe acute graft versus host disease (GvHD) had a negative impact on OS (p < 0.001). Development of chronic GvHD showed a trend to a better OS (p = 0.085) and DFS (p = 0.199). No impact was seen for the intensity of conditioning. Conclusion: Development of chronic GvHD but not the conditioning regimen improved the outcome after alloHSCT for advanced malignancies, underlining the importance of immunological rather than cytotoxic effects. 
Patients, Conditioning Regimen and Postgrafting Immunosuppression
Anadvancedstageofadiseasewasdefinedasrefractorydisease(RD), partialremission(PR)ormorethan2completeremissions(CR)attime ofalloHSCT [8] .Amajorityofthe401patientshadacutemyeloidleuke-mia (AML, n = 188) or non-Hodgkin's lymphoma (NHL, n = 80), followed by patients with myeloproliferative syndromes (MPS, n = 54), acute lymphoblastic leukemia (ALL, n = 47), multiple myeloma (MM, n = 24) or Hodgkin's disease (HD, n = 8 
Introduction
Treatment of malignant hematological diseases has been dramatically improved by the introduction of allogeneic hematopoietic stem cell transplantation (alloHSCT) [1] . Factors influencing the outcome after alloHSCT include tumor burden, donor selection, disease stage, the development of graft versus host disease (GvHD) and the graft composition [2] [3] [4] [5] [6] [7] . Despite the fact that the outcome after alloHSCTinrelapsedorrefractoryhematologicaldiseasesis poor, it is often performed since it is the only remaining curative option. However, this procedure is debatable. Due to its high morbidity and mortality, it potentially shortens the remaininglifetimeofpatientswithoutanyclinicalbenefit. Therefore, decisions regarding the appropriateness of alloHSCTforagivenpatientshouldinvolvecarefulconsiderationoftherisksassociatedwithalloHSCTandthelikelihood of cure. The intention of this retrospective analysis was to investigate, by identifying parameters with prognostic influence, which patients suffering from advanced hematological diseasecouldbenefitfromanalloHSCTandshouldtherefore beofferedthisprocedure. Thepatientsreceivedvariousconditioningregimensandimmunosuppression protocols. The majority were treated with a reduced-intensity conditioning(RIC,n=334)protocol,54patientsreceivedmyeloablative conditioning (MAC) and 13 patients were transplanted after non-myeloablativeconditioning.GvHDwasevaluatedaccordingtotheKeystone criteria(acute(a)GvHD)andtheclassificationaccordingtoShulmanet al.(chronic(c)GVHD) [9, 10] .
Statistical Analysis
AlldatawerestoredandanalyzedusingtheSPSSstatisticalpackage17.0 (SPSSInc.Chicago,IL,USA).StatisticalanalysiswasrealizedinagreementwithStatisticalGuidelinesofEBMT(EuropeanGroupforBlood and Marrow Transplantation). The statistics computed included mean andstandarddeviationsofcontinuousvariables,frequenciesandrelative frequencies of categorical factors. The Cox proportional hazards model wasusedtoassesstheindependenceofoverallsurvival(OS)anddiseasefree survival (DFS) from prognostic factors. First, univariate analyses were performed to reveal unadjusted significant associations between prognostic variables and OS or DFS. Thereafter, variables yielding pvalues≤0.15intheunivariateanalysiswereenteredinthemultivariate modeltohighlightadjustedassociationsbetweentheoutcomeandcovariates that were of borderline significance in univariate analysis. The impactofanaGvHDandcGvHDeventwasevaluatedbyincludingitas time-dependentcovariateT_COVintheCoxmodel.Allpvaluesresulted from2-sidedstatisticaltests,andp≤0.05wasconsideredtobesignificant. OS was defined as the time between transplantation and death (independent of the cause of death). DFS was defined as CR until relapse, death or last contact, whichever occurred first. Factors analyzed in this studywereage,sex,diseasecategory(myeloidvs.lymphoid),specificunderlyingdisease,intensityofconditioning,stemcellsource,performance status,anddevelopmentofGvHD.
Results
Theresultsreportedherecomefrom401patients,treatedat 3 different centers, who had advanced hematological malignancies [8] andwhoreceivedalloHSCT.Themedianfollowuptimewas282days (range3-3,607days) Diseases with the best outcome were MPS and NHL followedbyAMLandMM.Noneofthepatientswithadvanced ALL or HD who were not in remission showed a long OS, althoughthenumberofpatientswithHD(n=8)includedin the analysis was rather small. In 70% of patients with ALL (samplesizen=47)alloHSCTwasperformedinthepresence of active relapsed disease, which may explain the worse outcome.Inaddition,only17.0%ofpatientswithALLdevel-opedcGvHD.
The development of cGvHD was identified as important for OS, as shown in the multivariate analysis: patients with cGvHD showed a trend towards a better OS (p = 0.085, table 2a). On the other hand, the intensity of conditioning ( fig.2a) ,whichwasidentifiedasaparameterwithborderline significanceinunivariateanalyses(p=0.105),lostitsimpact inmultivariateanalysis(p=0.697,table2a).
For DFS, only the underlying disease had an impact in multivariateanalysis(p=0.011,table2b).ALL(p=0.005,adjusted hazard ratio (aHR) 3.00), HD (p = 0.025, aHR 3.72), MM(p=0.055,HR2.39)andAML(p=0.131,aHR1.65)had Noneoftheremainingparametersevaluatedinthisanalysis(age,donor-recipientgender,diseasecategory(myeloidvs. lymphoid), stem cell source or performance status) had a borderlineimpactonDFSorOSinunivariateanalysis.
Discussion
Sincetheoutcomeforpatientswithadvancedhematological diseaseispoor,analloHSCTisoftenperformedastheonly remaining curative option. However, this approach remains debatable [11] because of the severe adverse effects, the questionable outcome and the costs. Therefore, to facilitate thedecisionfororagainstanalloHSCTinaparticularsituation, knowledge of the general outcome in a given disease situation is crucial. The aim of this analysis was to identify parameters with prognostic influence after alloHSCT in advanced hematological diseases to identify malignancies in advancedstagesinwhichalloHSCTisareasonableoption. TheOSandtheDFSat2and5yearsinthisstudywas37.1 and 27.3%, and 29.1 and 21.1%, respectively. In a study by Schmidetal. [12] ,103patientswithrefractoryAMLreceived a sequential regimen of chemotherapy, RIC for alloHSCT, andprophylacticdonorlymphocytetransfusion.Inthatstudy, with a 25-month median follow-up, OS at 2 years was 40% and at 4 years 32%; the respective leukemia-free survival (LFS)was37%,and30%.Oyekunleetal.reportedtheresults of44patientswithrefractoryacuteleukemiawhounderwent alloHSCTafterMAC [13] .OSandprogression-freesurvival (PFS)after5yearswas28and26%,respectively.Hosingetal. identified tumor burden as a prognostic factor for survival afterasecondtransplantforAML.TheOSinthisgroupwas 6 months, but a subset of patients who had a low leukemia burdenatthetimeofthesecondtransplanthada5-yearsurvivalof25%comparedto12%inthosewithahighleukemia burden [5] . Robinson et al. [14] reported the outcome for 188patientswithNHLafteralloHSCT;theOSafter2years was 50%. The probability of having RD after 1 year for patientswithchemoresistantandchemosensitivediseasewere 75and25%,respectively(p=0.001).ThePFSat1yearwas 46%,andwassignificantlybetterforthosewithchemosensitiveHDandlow-gradeNHL.Kennedyetal.reportedtheresultsofpatientswithadvancedMMafteralloHSCTfollowing MAC [15] . Median OS, PFS, and event-free survival (EFS) were 28, 66 and 13 months, respectively, with a 5-year OS, PFS,andEFSof40,54and24%.
Throughamultivariateanalysis,weidentifiedALLasan underlyingdiseaseandthedevelopmentofaGvHDassignificantfactorsimpairingOS.cGvHDshowedatrendtowardsa betterOSandDFS(table2).Ontheotherhand,theintensity of conditioning appeared to have no impact on OS or DFS ( fig.2aandb,table2 ).Thismayindicatetheeffectivenessof immunologicaleffectsagainstadvanceddiseases,andthesusceptibilityofheavilypretreatedpatientstotreatment-related mortality induced by standard-dose MAC. The failure to achieve long-term OS in patients with advanced ALL may havebeenduetothelowrateofcGvHDintheevaluatedcohort.However,arecentpublicationdemonstratedacomplete failure of haploidentical HSCT in patients with ALL who werenotinremission,indicatingthelimitationsofagraftversusleukemiaeffectinpatientswithALL [16] .FromtheseresultsitcanbeassumedthatforpatientswithadvancedALL achievementofaCRwithlowdiseaseburdenpre-transplant iscrucialforOS [17] .
Theresultswepresenthereareinlinewithothers,e.g.the reported outcome of 71 patients after a second alloHSCT [18] . The predicted OS and transplant-related mortality (TRM) at 2 years were 28 and 27%, respectively. TRM was significantly lower in those who relapsed late following the firstalloHSCT(2years:17vs.38%inearlyrelapses;p=0.03). 2 factors were significantly associated with a better OS: late relapse (p = 0.014) and cGvHD following the second transplant (p = 0.014). Another study also showed the effect of cGvHDontheoutcomeafteralloHSCT [19] .Inaretrospective analysis of the International Bone Marrow Transplant Registry, patients with extensive cGvHD experienced fewer relapsesattheexpenseofhighertreatment-relatedmortality.
Kahletal.usedaregimenthatreliedvirtuallyentirelyon graftversustumoreffectsforeradicatingmalignancies [20] .In a retrospective analysis that included 834 patients (median age, 55; range, 5-74 years) with hematological malignancies, patients were grouped in different risk groups for relapse afternon-myeloablativealloHSCT,implyingavariablesensitivityforGvHD [20] .Patientswithchroniclymphocyticleukemia(CLL)andMMinCR,low-gradeormantlecellNHL (CR+PR),orhigh-gradeNHLinCRhadthelowestrelapse rates(0.00-0.24;lowrisk).Incontrast,patientswithadvanced myeloid and lymphoid malignancies had relapse rates of >0.52(highrisk).Patientswithlymphoproliferativediseases not in CR (except HD and high-grade NHL) and myeloid malignancies in CR had rates of 0.26-0.37 (standard risk). Diseasesgroupedinthehigh-riskgroup(AML,MPS)hada betteroutcomeinourstudy,probablybecauseofthehigher portion of RIC included here. It could be argued that after non-MAC,thenumbersofcancercellspresentatHSCTshift thebalanceintheirfavor,andthey'outproliferate'thedonor cytotoxicimmunecellsinamajorityofpatients.Therefore,a higher intensity of conditioning (RIC, but probably not MAC)isrequiredforoptimaltumorcellcontrolandforthe establishmentofanadequateimmuneresponse.
Inconclusion,wefoundasignificantproportionofpatients with advanced hematological diseases who achieved longterm remission after alloHSCT, although the subgroup of patientswithALLdidnotbenefitfromalloHSCT.Sincethe development of cGvHD, but not the intensity of the conditioning,improvedtheoutcomeinthissetting,itappearsthat chemotherapyonlyplaysaroleforimmediatediseasecontrol, whereas immunological mechanisms are essential for the long-termcontrol.Therefore,tofurtherimprovetheoutcome inthesepatients,transplantprotocolswithafocusontheimmunologicalratherthancytotoxiceffectareurgentlyneeded. 
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